文献速递乳腺癌放疗

导管原位癌瘤床加量放疗的局部区域控制获益

Locoregional Control Benefit of a Tumor Bed Boost for Ductal Carcinoma In Situ.
PubMed 文献 · Adv Radiat Oncol · 2023-04-24

本研究回顾性分析2004至2018年在本机构接受保乳手术的1675例导管原位癌患者,其中1146例(68%)接受瘤床加量放疗。中位随访4.2年,加量组与未加量组的10年无复发生存率分别为88.8%和84.3%(P=0.3),单因素和多因素分析均未显示加量放疗与局部区域复发相关。

要点

  • 1675例导管原位癌保乳术后患者中,1146例(68%)接受瘤床加量放疗,536例(32%)接受激素治疗。
  • 加量组10年无复发生存率为88.8%,未加量组为84.3%(P=0.3),差异未达统计学显著。

核心结论

  • 在导管原位癌保乳手术患者中,瘤床加量放疗与局部区域复发或无复发生存无关。
  • 尽管加量组不良特征占多数,其结局与未加量组相似,提示加量可能减轻高危特征患者的复发风险。
  • 正在进行的 study 将进一步阐明瘤床加量对疾病控制率的影响程度。

研究设计与样本

  • 研究为回顾性队列,纳入2004至2018年在本机构接受保乳手术的导管原位癌患者,共1675例。
  • 采用单因素和多因素Cox模型评估患者及肿瘤特征与结局的关系,Kaplan-Meier法估计无复发生存率。

主要发现

  • 患者中位年龄56岁(四分位距49-64岁),加量放疗1146例(68%),激素治疗536例(32%)。
  • 中位随访4.2年(四分位距1.4-7.0年),观察到61例局部区域复发事件(56例局部、5例区域)和21例死亡。
  • 加量放疗在年轻患者(P<.001)、切缘阳性或接近(P<.001)、肿瘤较大(P<.001)及分级较高(P=.025)者中更常见。
  • 加量组10年无复发生存率为88.8%,未加量组为84.3%(P=.3),单因素和多因素分析均未显示加量放疗与局部区域复发的关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy (RT) after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) reduces invasive and in situ recurrences. Whereas landmark studies suggest that a tumor bed boost improves local control for invasive breast cancer, the benefit in DCIS remains less certain. We evaluated outcomes of patients with DCIS treated with or without a boost. METHODS AND MATERIALS: The study cohort comprised patients with DCIS who underwent BCS at our institution from 2004 to 2018. Clinicopathologic features, treatment parameters, and outcomes were ascertained from medical records. Patient and tumor characteristics were evaluated relative to outcomes using univariable and multivariable Cox models. Recurrence-free survival (RFS) estimates were generated using the Kaplan-Meier method. RESULTS: We identified 1675 patients who underwent BCS for DCIS (median age, 56 years; interquartile range, 49-64 years). Boost RT was used in 1146 cases (68%) and hormone therapy in 536 (32%). At a median follow-up of 4.2 years (interquartile range, 1.4-7.0 years), we observed 61 locoregional recurrence events (56 local, 5 regional) and 21 deaths. Univariable logistic regression demonstrated that boost RT was more common among younger patients (P < .001) with positive or close margins (P < .001) and with larger tumors (P < .001) of higher grade (P = .025). The 10-year RFS rate was 88.8% among those receiving a boost and 84.3% among those without a boost (P = .3), and neither univariable nor multivariable analyses revealed an association between boost RT and locoregional recurrence. CONCLUSIONS: Among patients with DCIS who underwent BCS, use of a tumor bed boost was not associated with locoregional recurrence or RFS. Despite a preponderance of adverse features among the boost cohort, outcomes were similar to those of patients not receiving a boost, suggesting that a boost may mitigate risk of recurrence among patients with high-risk features. Ongoing studies will elucidate the extent to which a tumor bed boost influences disease control rates.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Dreyfuss AD, Max D, Flynn J, et al. Locoregional Control Benefit of a Tumor Bed Boost for Ductal Carcinoma In Situ. Adv Radiat Oncol. 2023. PMID: 37250283. doi:10.1016/j.adro.2023.101254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。